Neurological Recovery Following NOS-SACD

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-40
SponsorNottingham University Hospitals NHS Trust

About this trial

Nitrous oxide has become an increasingly popular recreational drug amongst young people, particularly at festivals, nightclubs and parties. Considering the drug is not illegal to possess, has low cost in the form of 'whippets' and can be easily purchased online, it has become the second most commonly used recreational drug amongst people aged 16-24 in the UK. However, nitrous oxide is known to irreversibly inactivate the functioning of vitamin B12, a vitamin required for the maintenance and proper functioning of nerves in the spinal cord. Neurological symptoms in this population have been reported in around 3.4% of nitrous oxide users, although the true incidence is expected to be higher as the cases being reported by UK hospitals continues to rise.

Patients may present with adverse neurological symptoms like tingling, weakness, coordination and mobility problems. Currently, studies reviewing the functional recovery of these patients have been limited by a retrospective study design, short follow up duration and being limited to small cohort sizes. This is in part linked to patient non-compliance and non-attendance at follow-up appointments. The investigators will therefore prospectively recruit all patients presenting with these symptoms and continue to collect data relating to their neurological recovery for 12 months. Data collection will be remote to ensure it is of low burden to the participants. This will allow the investigating team and others to fully appraise the severity of these toxic neuropathies and understand how best to manage their follow up.

Eligibility criteria

Qualifiers

Any patient first presented with paraesthesia, weakness, ataxia or gait disturbance with a history of NOS use (age limit 16-40) as of 19/08/2024

Patients who can read and write in English, so that they can complete the questionnaires.

Patients must have received a definitive consultant neurologist confirmed diagnosis of NOS-induced neurological damage. This is possible as all eligible patients will have been reviewed by the neurology team prior to study involvement.

Disqualifiers

Patients currently taking part in the longitudinal study.

Patients who report previously (clinical history) or currently (PHQ-2, clinical history) experiencing mental health difficulties.

Trial design

Treatments tested in this trial

  • Observational study with no interventions

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

Nottingham University Hospitals NHS Trust

Lead sponsor

Barts & The London NHS Trust

Collaborator

Northern Care Alliance NHS Foundation Trust

Collaborator

University Hospital Birmingham NHS Foundation Trust

Collaborator